Josie Godfrey is an independent strategic adviser on health policy, market access and advocacy, with 18 years' experience shaping how rare and complex treatments are assessed and funded. She set up NICE's Highly Specialised Technologies programme, now an international benchmark for evaluating therapies for rare conditions. She has since advised pharmaceutical companies, trade bodies, HTA agencies and patient organisations in the UK and internationally. Since 2018 she has worked with Fleur Chandler and Emily Reuben of Duchenne UK to build Project HERCULES into a globally recognised model of collaborative evidence generation for HTA, and acts as its Strategic Director. Josie is Director of JG Zebra Consulting and co-lead investigator of RareCare, the NIHR-funded evaluation of the UK Rare Disease Framework.